These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 1676808)

  • 1. Influence of candoxatril on plasma brain natriuretic peptide in heart failure.
    Lang CC; Motwani J; Coutie WJ; Struthers AD
    Lancet; 1991 Jul; 338(8761):255. PubMed ID: 1676808
    [No Abstract]   [Full Text] [Related]  

  • 2. The effect of the neutral endopeptidase inhibitor drug, candoxatril, on circulating levels of two of the most potent vasoactive peptides.
    McDowell G; Coutie W; Shaw C; Buchanan KD; Struthers AD; Nicholls DP
    Br J Clin Pharmacol; 1997 Mar; 43(3):329-32. PubMed ID: 9088591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clearance of brain natriuretic peptide in patients with chronic heart failure: indirect evidence for a neutral endopeptidase mechanism but against an atrial natriuretic peptide clearance receptor mechanism.
    Lang CC; Motwani JG; Coutie WJ; Struthers AD
    Clin Sci (Lond); 1992 Jun; 82(6):619-23. PubMed ID: 1320540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the short-term effects of candoxatril, an orally active neutral endopeptidase inhibitor, and frusemide in the treatment of patients with chronic heart failure.
    Northridge DB; Newby DE; Rooney E; Norrie J; Dargie HJ
    Am Heart J; 1999 Dec; 138(6 Pt 1):1149-57. PubMed ID: 10577447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of endopeptidase EC 3.4.24.11 by candoxatril lowered blood pressure and increased urinary but not plasma atrial natriuretic peptide in essential hypertension.
    Tunny TJ; Ziesak MD; Armstrong R; Klemm SA; Stowasser M; Finn WL; Gordon RD
    J Hypertens Suppl; 1993 Dec; 11(5):S222-3. PubMed ID: 8158355
    [No Abstract]   [Full Text] [Related]  

  • 6. Neutral endopeptidase 24.11 inhibition may not exhibit beneficial haemodynamic effects in patients with congestive heart failure.
    Kentsch M; Otter W; Drummer C; Nötges A; Gerzer R; Müller-Esch G
    Eur J Clin Pharmacol; 1996; 51(3-4):269-72. PubMed ID: 9010697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of heart failure with plasma natriuretic peptides.
    Penney MD; Hampton D
    Lancet; 1998 Feb; 351(9100):444; author reply 445. PubMed ID: 9482328
    [No Abstract]   [Full Text] [Related]  

  • 8. Assessment of heart failure with plasma natriuretic peptides.
    McMurray J; Davie AP; McClure SJ
    Lancet; 1998 Feb; 351(9100):444; author reply 445. PubMed ID: 9482327
    [No Abstract]   [Full Text] [Related]  

  • 9. [Human atrial natriuretic peptide (hANP), human brain natriuretic peptide (hBNP)].
    Tsujino M; Hirata Y
    Nihon Rinsho; 1995 Mar; 53 Su Pt 2():737-40. PubMed ID: 8753347
    [No Abstract]   [Full Text] [Related]  

  • 10. Responses of plasma concentrations of A type natriuretic peptide and B type natriuretic to alacepril, an angiotensin-converting enzyme inhibitor, in patients with congestive heart failure.
    Cheung B
    Br Heart J; 1995 Jun; 73(6):584-5. PubMed ID: 7626365
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of ACE inhibitors on the atrial natriuretic peptides in heart failure.
    Struthers AD
    Br Heart J; 1994 Dec; 72(6):504. PubMed ID: 7857729
    [No Abstract]   [Full Text] [Related]  

  • 12. Influence of age on natriuretic peptides in patients with chronic heart failure: a comparison between ANP/NT-ANP and BNP/NT-proBNP.
    Hogenhuis J; Voors AA; Jaarsma T; Hillege HL; Boomsma F; van Veldhuisen DJ
    Eur J Heart Fail; 2005 Jan; 7(1):81-6. PubMed ID: 15642536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of endopeptidase inhibition (candoxatril) in congestive heart failure.
    Elsner D; Müntze A; Kromer EP; Riegger GA
    Am J Cardiol; 1992 Aug; 70(4):494-8. PubMed ID: 1386491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension.
    Bevan EG; Connell JM; Doyle J; Carmichael HA; Davies DL; Lorimer AR; McInnes GT
    J Hypertens; 1992 Jul; 10(7):607-13. PubMed ID: 1321186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natriuretic peptides in detection of heart failure.
    Dickstein K
    Lancet; 1998 Jan; 351(9095):4. PubMed ID: 9433417
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of the maze procedure for atrial fibrillation on atrial and brain natriuretic peptide.
    Nakamura M; Niinuma H; Chiba M; Ueshima K; Arakawa N; Yagi Y; Kawazoe K; Hiramori K
    Am J Cardiol; 1997 Apr; 79(7):966-70. PubMed ID: 9104915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concentrations of brain natriuretic peptide in treated congestive heart failure.
    Togashi K; Ando K; Hasegawa N; Kawakami M; Marumo F
    Clin Chem; 1991 May; 37(5):765. PubMed ID: 1827759
    [No Abstract]   [Full Text] [Related]  

  • 18. Increased plasma levels of brain natriuretic peptide in patients with isolated diastolic dysfunction.
    Lang CC; Prasad N; McAlpine HM; Macleod C; Lipworth BJ; MacDonald TM; Struthers AD
    Am Heart J; 1994 Jun; 127(6):1635-6. PubMed ID: 8197998
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of renal neutral endopeptidase inhibition on sodium excretion, renal hemodynamics and neurohormonal activation in patients with congestive heart failure.
    Kimmelstiel CD; Perrone R; Kilcoyne L; Souhrada J; Udelson J; Smith J; de Bold A; Griffith J; Konstam MA
    Cardiology; 1996; 87(1):46-53. PubMed ID: 8631044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospects for using a blood sample in the diagnosis of heart failure.
    Struthers AD
    QJM; 1995 May; 88(5):303-6. PubMed ID: 7796082
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.